CG Oncology Inc.
CGON
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.6B
$74.67
▲ +0.46%
P/E
-27.66
Mkt Cap
$6.6B
52-Wk Range
$32.08–$80.97
52-Week Range
$32.08 - $80.97
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 121.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage in BCG-unresponsive NMIBC treatment segment
- Proprietary cretostimogene technology with bladder-sparing mechanism
- Focused pipeline reducing development complexity and capital requirements
- Large addressable market with significant unmet medical need
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Revenue decline expected
Clinical trial progression and regulatory milestones for cretostimogene
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+37.3% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CGON right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 6, 2026
Reported EPS of -$0.90 vs -$0.66 consensus (-35.5% surprise). Revenue of $1.2M vs $360.8K expected (+220.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-35.5%
Revenue trend · last 8Q
—
—
-90%
-100%
+3774%
+409%
+1983%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$43.0K
$456.0K
$52.0K
$0
$1.7M
$2.3M
$1.1M
$1.2M
Margins · last 8Q
Gross
—
Profit
-6832.8%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 29, 2026
vs Industry
How CGON stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related